(Total Views: 415)
Posted On: 05/08/2020 12:07:54 PM
Post# of 8587
Re: Belgian Waffle #2430
Nothing specific on BIEL that I saw Belgian
Colfax saw a significant revenue drop in both their Medical and Fabrication divisions starting in March.
Here a couple of paragraphs, those interested can read the full CC at the link below:
MedTech Q1 results are included on slide seven. We were on a strong growth trajectory until mid-March, and pro forma sales of $291 million ultimately landed at about the same level as last year with the benefit of a few extra selling days that were reversed in the fourth quarter. We believe the business lost $25 million or more of revenue in March due to COVID.
Lower revenues and the follow-on effect on operating efficiency contributed to reduced EBITA and margins in the quarter. The cost actions that were developed in March are now fully deployed, and business leaders have thoughtfully reprioritized spending to protect growth investments, including key product launches later this year.
https://www.nasdaq.com/articles/colfax-corp-c...2020-05-08
Colfax saw a significant revenue drop in both their Medical and Fabrication divisions starting in March.
Here a couple of paragraphs, those interested can read the full CC at the link below:
MedTech Q1 results are included on slide seven. We were on a strong growth trajectory until mid-March, and pro forma sales of $291 million ultimately landed at about the same level as last year with the benefit of a few extra selling days that were reversed in the fourth quarter. We believe the business lost $25 million or more of revenue in March due to COVID.
Lower revenues and the follow-on effect on operating efficiency contributed to reduced EBITA and margins in the quarter. The cost actions that were developed in March are now fully deployed, and business leaders have thoughtfully reprioritized spending to protect growth investments, including key product launches later this year.
https://www.nasdaq.com/articles/colfax-corp-c...2020-05-08
(0)
(0)
